Mineral and bone disorders in patients with chronic obstructive pulmonary disease combined with chronic kidney disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic obstructive pulmonary disease (Copd) is an important medical and social problem that is connected not only with its high prevalence in the population, increasing mortality, but also with a significant frequency of comorbidity due to systemic effects of copd. Small number of recent studies highlights the relationship of copd with development of kidney dysfunction. Mineral and bone disorders occur in both of these nosologies, which cannot fail to attract the attention of researchers to find the possibility of additional monitoring and improvement of the course of disease in the future. This review considers the main risk factors for the development of mineral and bone disorders, their pathogenetic and clinical aspects with comorbid combination of copd and ckd.

Full Text

Restricted Access

References

  1. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А. С., Лещенко И.В., Мещерякова Н.Н., Овчаренко С.И., Шмелев Е.И. Российское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014;3:15-54.
  2. Choudhury G., Rabinovich R., MacNee W. Comorbidities and systemic effects of chronic obstructive pulmonary disease. Clin. Chest Med. 2014; 35(1):101-130.
  3. Ehteshami-Afshar S., FitzGerald J.M., Doyle-Waters M.M., Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Int. J. Tuberc. Lung. Dis. 2016;20(1):11-23.
  4. Campo G., Pavasini R., Malagu M., Mascetti S., Biscaglia S., Ceconi C., Papi A., Contoli M. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc. Drugs Ther. 2015;29(2):147-157.
  5. Gjerde B., Bakke P.S., Ueland T., Hardie J.A., Eagan T.M. The prevalence of undiagnosed renal failure in a cohort of COPD patients in western Norway. Respir. Med. 2012;106(3):361-366.
  6. Navaneethan S.D., Schold J.D., Huang H. Mortality Outcomes of Patients with Chronic Kidney Disease and Chronic Obstructive Pulmonary Disease. Am. J. Nephrol. 2016;43(1):39-46.
  7. Elmahallawy 1.1., Qora M.A., Prevalence of chronic renal failure in COPD patients. Egyptian Journal of Chest Diseases and Tuberculosis. 2013;62(2):221-227.
  8. Chen C.-Y., Liao K.-M. Chronic Obstructive Pulmonary Disease is associated with risk of Chronic Kidney Disease: A Nationwide Case-Cohort Study. Sci Rep. 2016;6:25855.
  9. Yoshizawa T., Okada K., Furuichi S., Ishiguro T., Yoshizawa A., Akahoshi T., Gon Y., Akashiba T., Hosokawa Y., Hashimoto S. Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:1283-1289.
  10. Болотова Е.В., Дудникова А.В. Особенности дисфункции почек у пациентов с хронической обструктивной болезнью легких. Клиническая нефрология. 2015;2-3:27-32.
  11. Смирнов А.В., Добронравов В.А., Каюков И.Г. и др. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Национальные рекомендации. Нефрология. 2012;16(1):89-115.
  12. Моисеев В.С., Мухин Н.А., Смирнов А.В., Кобалава Ж.Д., Бобкова И.Н., Виллевальде С.В., Ефремовцева М.А., Козловская Л.В., Швецов М.Ю., Шестакова М.В. Сердечно-сосудистый риск и стратегии кардионефропротекции. Клиническая нефрология. 2014;2:4-29.
  13. Клинические практические рекомендации по диагностике, оценке, профилактике и лечению минеральных и костных нарушений при хронической болезни почек (МКН-ХБП). Краткое изложение KDIGO. Под ред. А.М. Андрусева. Нефрология и диализ. 2011;13(1):8-12.
  14. Navaneethan S.D., Schold J.D., Huang H., Nakhoul G., Jolly S.E., Arrigain S., Dweik R.A., Nally J.V. Jr. Mortality Outcomes of Patients with Chronic Kidney Disease and Chronic Obstructive Pulmonary Disease. Am. J. Nephrol. 2016;43(1):39-46.
  15. WHO Study Group on Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. Rome, 1992. Geneva, World Health Organization, 1994. URL: http://whqlibdoc.who.int/trs/WHO_TRS_843.pdf.
  16. Graat-Verboom L., Wouters E.F., Smeenk F.W., van den Borne B.E., Lunde R., Spruit M.A. Current status of research on osteoporosis in COPD: a systematic review. Eur. Respir. J. 2009;34(1):209-218.
  17. Kong X., Tang L., Ma X., Liu W., Wang Z., Cui M., Xu D. Relationship between mild-to-moderate chronic kidney disease and decreased bone mineral density in Chinese adult population. Int. Urol. Nephrol. 2015; 47(9):1547-1553.
  18. Myong J.-P., Kim H.-R., Koo J.-W., Park C.Y. Relationship between Bone Mineral Density and Moderate to Severe Chronic Kidney Disease among General Population in Korea. J. Korean Med. Sci. 2013;28(4):569-574. doi: 10.3346/jkms.2013.28.4.569.
  19. Рамочная конвенция ВОЗ по борьбе против табака. Женева, ВОЗ, 2003 URL: http://whqlibdoc.who.int/publications/2003/9789244591017_rus.pdf.
  20. Chen K., Bi J., Su Y., Chappell M.C., Rose J.C. Sex-Specific Changes in Renal Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Gene Expression and Enzyme Activity at Birth and Over the First Year of Life. Reprod. Sci. 2016;23(2):200-210.
  21. Sullivan J.C., Rodriguez-Miguelez P., Zimmerman M.A., Harris R.A. Differences in angiotensin (1-7) between men and women. Am. J. Physiol Heart Circ. Physiol. 2015;308(9):1171-1176.
  22. Cobo G., Hecking M., Port F.K., Exner I., Lindholm B., Stenvinkel P., Carrero J.J. Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. Clin. Sci. 2016;130(14):1147-1163.
  23. Omoloja A., Stolfi A., Chand D., Laskin B., Gipson D., Patel H., Smith J.A., Chishti A. Tobacco exposure in children and adolescents with chronic kidney disease: parental behavior and knowledge. A study from the Midwest Pediatric Nephrology Consortium. Clin. Nephrol. 2014;81(5):307-312.
  24. Alba M.M., Citarelli A.N., Menni F., Agricola M., Braicovich A., De Horta E., De Rosa F., Filanino G., Gaggiotti R., Junqueras N., Martinelli S., Milan A., Morales M.E., Setti S., Villalba D.O. Tobacco and end stage renal disease: a multicenter, cross-sectional study in Argentinian Northern Patagonia. Tob. Induc. Dis. 2015;13(1):28.
  25. Simonetti G.D., Schwertz R., Klett M., Hoffmann G.F., Schaefer F., Wühl E. Determinants of blood pressure in preschool children: the role of parental smoking. Circulation. 2011;123(3):292-298.
  26. Obert D.M., Hua P., Pilkerton M.E., Feng W., Jaimes E.A. Environmental tobacco smoke furthers progression of diabetic nephropathy. Am. J. Med. Sci. 2011;341(2):126-130.
  27. Kanis J.A., Johnell O., Oden A., Johansson H., De Laet C., Eisman J.A., Fujiwara S., Kroger H., McCloskey E.V., Mellstrom D., Melton L.J., Pols H., Reeve J., Silman A., Tenenhouse A. Smoking and fracture risk: a metaanalysis. Osteoporos Int. 2005;16(2):155-162.
  28. Tanaka H., Tanabe N., KawatoT., Nakai K., Kariya T., Matsumoto S., Zhao N., Motohashi M., Maeno M. Nicotine Affects Bone Resorption and Suppresses the Expression of Cathepsin K, MMP-9 and Vacuolar-Type H+-ATPase d2 and Actin Organization in Osteoclasts. PLoS ONE. 2013;8(3):e59402.
  29. Sundar I.K., Rahman I. Vitamin D Susceptibility of Chronic Lung Diseases: Role of Epigenetics. Front. Pharmacol. 2011;2:50.
  30. Chibalin A.V., Heiny J.A., Benziane B., Prokofiev A.V., Vasiliev A.V., Kravtsova V.V., Krivoi I.I. Chronic Nicotine Modifies Skeletal Muscle Na,K-ATPase Activity through Its Interaction with the Nicotinic Acetylcholine Receptor and Phospholemman. PLoS ONE. 2012;7(3):e33719.
  31. Cielen N., Maes K., Gayan-Ramirez G. Musculoskeletal Disorders in Chronic Obstructive Pulmonary Disease. BioMed Research International. 2014;2014:965764. doi: 10.1155/2014/965764.
  32. Liu W.-T., Kuo H.-P., Liao T.-H., Chiang L.L., Chen L.F., Hsu M.F., Chuang H.C., Lee K.Y., Huang C.D., Ho S.C. Low bone mineral density in COPD patients with osteoporosis is related to low daily physical activity and high COPD assessment test scores. Int. J. Chron. Obstruct Pulmon. Dis. 2015;10:1737-1744.
  33. Forli L., Mellbye O.J., Halse J., Bjortuft O., Vatn M., Boe J. Cytokines, bone turnover markers and weight change in candidates for lung transplantation. Pulm. Pharmacol. Ther. 2008;21(1):188-195.
  34. Singh B., Arora S., Khanna V. Association of severity of COPD with IgE and interleukin-1beta. Monaldi Arch. Chest Dis. 2010;73(2):86-87.
  35. Barreiro E., Peinado V.I., Galdiz J.B., Ferrer E., Marin-Corral J., Sanchez F., Gea J., Barberà J.A.; ENIGMA in COPD Project. Cigarette smoke-induced oxidative stress: a role in chronic obstructive pulmonary disease skeletal muscle dysfunction. Am. J. Respir. Crit. Care Med. 2010;182(4):477-488.
  36. Stanojkovic I., Kotur-Stevuljevic J., Milenkovic B., Spasic S., Vujic T., Stefanovic A., Llic A., Ivanisevic J. Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbation. Respir. Med. 2011;105(1):31-37.
  37. Powers S.K., Smuder A.J., Judge A.R. Oxidative stress and disuse muscle atrophy: cause or consequence? Curr. Opin. Clin. Nutr. Metab. Care. 2012;15(3):240-245.
  38. Vermeeren M.A., Creutzberg E.C., Schols A.M., Postma D.S., Pieters W.R., Roldaan A.C., Wouters E.F.; COSMIC Study Group. Prevalence of nutritional depletion in large out-patient population of patients with COPD. Respir. Med. 2006;100(8):1349-1355.
  39. Itoh M., Tsuji T., Nemoto K., Nakamura H., Aoshiba K. Undernutrition in Patients with COPD and Its Treatment. Nutrients. 2013;5(4):1316-1335.
  40. Watanabe R., Tanaka T., Aita K., Hagiya M., Homma T., Yokosuka K., Yamakawa H., Yarita T., Tai N., Hirano J., Inoue D., Okazaki R. Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function. J. Bone Miner. Metab. 2015;33(4):392-400.
  41. Rabinovich R.A., Ardite E., Mayer A.M., Polo M.F., Vilarô J., Argiles J.M., Roca J. Training depletes muscle glutathione in patients with chronic obstructive pulmonary disease and low body mass index. Respiration. 2006;73:757-761.
  42. Romme E.A., Rutten E.P., Smeenk F.W., Spruit M.A., Menheere P.P., Wouters E.F. Vitamin D status is associated with bone mineral density and functional exercise capacity in patients with chronic obstructive pulmonary disease. Ann. Med. 2013;45(1):91-96.
  43. Persson L.J., Aanerud M., Hiemstra P.S., Hardie J.A., Bakke P.S., Eagan T.M. Chronic obstructive pulmonary disease is associated with low levels ofvitamin D. PLoS One. 2012;7(6):e38934.
  44. Janssens W., Bouillon R., Claes B., Carremans C., Lehouck A., Buysschaert I., Coolen J., Mathieu C., Decramer M., Lambrechts D. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the Vitamin D-binding gene. Thorax. 2010;65:215-220.
  45. Kim S.W., Lee J.M., Ha J.H., Kang H.H., Rhee C.K., Kim J.W., Moon H.S., Baek K.H., Lee S.H. Association between vitamin D receptor polymorphisms and osteoporosis in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:1809-1817.
  46. Skaaby T., Husemoen L.L.N., Thuesen B.H, Pisinger C., Jorgensen T., Fenger R.V., Linneberg A. Vitamin D Status and Chronic Obstructive Pulmonary Disease: A Prospective General Population Study. PLoS ONE. 2014;9(3):e90654.
  47. Hilger J., Friedel A., Herr R., Rausch T., Roos F., Wahl D.A., Pierroz D.D., Weber P., Hoffmann K. A systematic review of vitamin D status in populations worldwide. Br. J. Nutr. 2014;111:23-45.
  48. Ebeling P.R. Vitamin D and bone health: epidemiologic studies. Bonekey Rep. 2014;3:511.
  49. Brincat M., Gambin J., Brincat M., Calleja-Agius J. The role of vitamin D in osteoporosis. Maturitas. 2015;80(3):329-332.
  50. Pilz S., Tomaschitz A., Friedl C. Vitamin D status and mortality in chronic kidney disease. Nephrol. Dial. Transplant. 2011;26(11):3603-3609.
  51. Quarles L.D. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat. Rev. Endocrinol. 2012;8(5):276-286.
  52. Ford M.L., Smith E.R., Tomlinson L.A., Chatterjee P.K., Rajkumar C., Holt S.G. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol. Dial. Transplant. 2012;27:727-733.
  53. Гребенникова Т.А, Белая Ж.Е, Цориев Т.Т., Рожинская Л.Я., Мельниченко Г.А. Эндокринная функция костной ткани. Остеопороз и остеопатии. 2015;1:28-37.
  54. Мелентьева А.А., Барышева О.Ю., Везикова Н.Н., Хейфец Л.М. Роль фактора роста фибробластов 23 и фактора KLOTHO в развитии минерально-костных нарушений при хронической болезни почек. Курский научно-практический вестник «Человек и его здоровье». 2014;3:102-109.
  55. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82(7):737-747.
  56. Kraut J.A., Madias N.E. Metabolic acidosis: pathophysiology, diagnosis and management. Nat. Rev. Nephrol. 2010;6:274-285.
  57. Baptist A.P., Reddy R.C. Inhaled corticosteroids for asthma: are they all the same? J. Clin. Pharm. Ther. 2009;34:1-12.
  58. Loke Y.K., Cavallazzi R., Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational. Thorax. 2011;66:699-708.
  59. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., Yates J.C., Vestbo J.; TORCH investigators. Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. N. Eng. J. Med. 2007;356(8):775-789.
  60. Burge P.S., Calverley P.M, Jones P.W., Spencer S., Anderson J.A., Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297-1303.
  61. Pollett S., Graves B., Richards B., MacLeod C. Avascular necrosis in a HIV patient receiving ritonavir and inhaled fluticasone. Int. J. STD AIDS. 2014;25:458-460.
  62. Kaviani N., Bukberg P., Manessis A., Yen V., Young I. Iatrogenic osteoporosis, bilateral HIP osteonecrosis, and secondary adrenal suppression in an HIV-infected man receiving inhaled corticosteroids and ritonavir-boosted highly active antiretroviral therapy. Endocr. Pract. 2011;17:74-78.
  63. Chee C., Sellahewa L., Pappachan J.M. Inhaled Corticosteroids and Bone Health. Open Respir. Med. J. 2014;8:85-92.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies